Clinical trial
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of…
NCT00359892 · Gemin X, Industry · Completed
Key facts
| NCT number | NCT00359892 |
|---|---|
| Title | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma |
| Official title | A Multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma |
| Lead sponsor | Gemin X, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Obatoclax mesylate (GX15-070MS) |
| Enrollment | 13 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Nov 1, 2008 |
| First posted | Aug 3, 2006 |
| Last update posted | Aug 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: